Cited by 149Diabetes Treatment and ManagementHeart Failure Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database

Open access
MacDonald, Michael R., Eurich, Dean T., Majumdar, Sumit R., Lewsey, James D., Bhagra, Sai, Jhund, Pardeep S., Petrie, Mark C., McMurray, John J.V. +2 more·2010·Diabetes Care

Abstract

OBJECTIVE: Diabetes and heart failure commonly coexist, and prior studies have suggested better outcomes with metformin than other antidiabetic agents. We designed this study to determine whether this association reflects a beneficial effect of metformin or a harmful effect of other agents. RESEARCH DESIGN AND METHODS: We performed a case-control study nested within the U.K. General Practice Research Database cohort in which diagnoses were assigned by each patient's primary care physician. Case subjects were patients 35 years or older, newly diagnosed with both heart failure and diabetes after January 1988, and who died prior to October 2007. Control subjects were matched to case subjects based on age, sex, clinic site, calendar year, and duration of follow-up. Analyses were adjusted for comorbidities, A1C, renal function, and BMI. RESULTS: The duration of concurrent diabetes and heart failure was 2.8 years (SD 2.6) in our 1,633 case subjects and 1,633 control subjects (mean age 78 years, 53% male). Compared with patients who were not exposed to antidiabetic drugs, the current use of metformin monotherapy (adjusted odds ratio 0.65 [0.48-0.87]) or metformin with or without other agents (0.72 [0.59-0.90]) was associated with lower mortality; however, use of other antidiabetic drugs or insulin was not associated with all-cause mortality. Conversely, the use of ACE inhibitors/angiotensin receptor blockers (0.55 [0.45-0.68]) and beta-blockers (0.76 [0.61-0.95]) were associated with reduced mortality. CONCLUSIONS: Our results confirm the benefits of trial-proven anti-failure therapies in patients with diabetes and support the use of metformin-based strategies to lower glucose.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-2227

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J. V., Petrie, J. R., & McAlister, F. A.
Affiliations
  • Golden Jubilee National Hospital (GB)
  • University of Alberta (CA)
  • Department of Public Health and Health Policy, University of Glasgow, Glasgow, Scotland;
  • Sunderland Royal Hospital (GB)
  • British Heart Foundation (GB)
Corresponding author
McAlister, Finlay A.
Venue
Diabetes Care
Published
2010-06-01
Volume
33
Issue
6
Pages
1213-1218
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2146723462
Cited by
149
References
24
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 9 · 2021: 9 · 2020: 19 · 2019: 12 · 2018: 13 · 2017: 16 · 2016: 14 · 2015: 6 · 2014: 11 · 2013: 11 · 2012: 12
FWCI
8.45
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, heart failure, metformin, antidiabetic drugs, insulin, all-cause mortality, ACE inhibitors, angiotensin receptor blockers, beta-blockers, comorbidities, mortality
MeSH terms
Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Aspirin, Diabetes Mellitus, Type 2, Digoxin, Female, United Kingdom, Heart Failure, Humans, Hypoglycemic Agents, Male, Metformin, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review